抗肿瘤药物的心脏毒性及预防  

Cardiotoxicity and prevention of antineoplastic drugs

作　　者：艾云琨 邢丽娜[1] AI Yun-kun;XING Li-na(Department of Radiotherapy,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院放疗科,黑龙江哈尔滨150081

出　　处：《心血管康复医学杂志》2023年第3期258-261,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：心脏毒性,是抗肿瘤药物严重的并发症。近年来,随诊抗肿瘤药物的发展,多药联合治疗可显著延长患者的生存期,但此方式加重心脏毒性。了解心脏毒性的发生机制,及时发现并进行预防,可减少心血管意外的发生。本文就抗肿瘤药物的心脏毒性预防及管理进行综述。Cardiotoxicity is a serious complication of antineoplastic drugs.In recent years,with the development of antineoplastic drugs,multi-drug combination therapy can significantly prolong the survival period of patients.But it aggravates cardiotoxicity.Understanding the mechanism of cardiotoxicity,timely identification and prevention can reduce the occurrence of cardiovascular accidents.The present article reviews the prevention and management of cardiotoxicity of antineoplastic drugs.

关 键 词：心脏毒素类 抗肿瘤药 预防和防护用药 

分 类 号：R979.1[医药卫生—药品]